OBJECTIVE: To determine the efficacy of oral supplementation of the gut enzyme intestinal alkaline phosphatase (IAP) in preventing antibiotic-associated infections from Salmonella enterica serovar Typhimurium (S. Typhimurium) and Clostridium difficile. BACKGROUND: The intestinal microbiota plays a pivotal role in human health and well-being. Antibiotics inherently cause dysbiosis, an imbalance in the number and composition of intestinal commensal bacteria, which leads to susceptibility to opportunistic bacterial infections. Previously, we have shown that IAP preserves the normal homeostasis of intestinal microbiota and that oral supplementation with calf IAP (cIAP) rapidly restores the normal gut flora. We hypothesized that oral IAP supplementation would protect against antibiotic-associated bacterial infections. METHODS: C57BL/6 mice were treated with antibiotic(s) ± cIAP in the drinking water, followed by oral gavage of S. Typhimurium or C. difficile. Mice were observed for clinical conditions and mortality. After a defined period of time, mice were killed and investigated for hematological, inflammatory, and histological changes. RESULTS: We observed that oral supplementation with cIAP during antibiotic treatment protects mice from infections with S. Typhimurium as well as with C. difficile. Animals given IAP maintained their weight, had reduced clinical severity and gut inflammation, and showed improved survival. CONCLUSIONS: Oral IAP supplementation protected mice from antibiotic-associated bacterial infections. We postulate that oral IAP supplementation could represent a novel therapy to protect against antibiotic-associated diarrhea (AAD), C. difficile-associated disease (CDAD), and other enteric infections in humans.
OBJECTIVE: To determine the efficacy of oral supplementation of the gut enzyme intestinal alkaline phosphatase (IAP) in preventing antibiotic-associated infections from Salmonella enterica serovar Typhimurium (S. Typhimurium) and Clostridium difficile. BACKGROUND: The intestinal microbiota plays a pivotal role in human health and well-being. Antibiotics inherently cause dysbiosis, an imbalance in the number and composition of intestinal commensal bacteria, which leads to susceptibility to opportunistic bacterial infections. Previously, we have shown that IAP preserves the normal homeostasis of intestinal microbiota and that oral supplementation with calfIAP (cIAP) rapidly restores the normal gut flora. We hypothesized that oral IAP supplementation would protect against antibiotic-associated bacterial infections. METHODS: C57BL/6 mice were treated with antibiotic(s) ± cIAP in the drinking water, followed by oral gavage of S. Typhimurium or C. difficile. Mice were observed for clinical conditions and mortality. After a defined period of time, mice were killed and investigated for hematological, inflammatory, and histological changes. RESULTS: We observed that oral supplementation with cIAP during antibiotic treatment protects mice from infections with S. Typhimurium as well as with C. difficile. Animals given IAP maintained their weight, had reduced clinical severity and gut inflammation, and showed improved survival. CONCLUSIONS:Oral IAP supplementation protected mice from antibiotic-associated bacterial infections. We postulate that oral IAP supplementation could represent a novel therapy to protect against antibiotic-associated diarrhea (AAD), C. difficile-associated disease (CDAD), and other enteric infections in humans.
Authors: Farzad Ebrahimi; Madhu S Malo; Sayeda Nasrin Alam; Angela K Moss; Halim Yammine; Sundaram Ramasamy; Brishti Biswas; Kathryn T Chen; Nur Muhammad; Golam Mostafa; H Shaw Warren; Elizabeth L Hohmann; Richard A Hodin Journal: J Gastrointest Surg Date: 2011-03-01 Impact factor: 3.452
Authors: Won Ho Yang; Douglas M Heithoff; Peter V Aziz; Markus Sperandio; Victor Nizet; Michael J Mahan; Jamey D Marth Journal: Science Date: 2017-12-22 Impact factor: 47.728
Authors: Florian Kühn; Ruifeng Duan; Matthias Ilmer; Ulrich Wirth; Fatemeh Adiliaghdam; Tobias S Schiergens; Joachim Andrassy; Alexandr V Bazhin; Jens Werner Journal: Visc Med Date: 2021-04-29
Authors: Madhu S Malo; Omeed Moaven; Nur Muhammad; Brishti Biswas; Sayeda N Alam; Konstantinos P Economopoulos; Sarah Shireen Gul; Sulaiman R Hamarneh; Nondita S Malo; Abeba Teshager; Mussa M Rafat Mohamed; Qingsong Tao; Sonoko Narisawa; José Luis Millán; Elizabeth L Hohmann; H Shaw Warren; Simon C Robson; Richard A Hodin Journal: Am J Physiol Gastrointest Liver Physiol Date: 2014-04-10 Impact factor: 4.052
Authors: Walker Julliard; Travis J De Wolfe; John H Fechner; Nasia Safdar; Rashmi Agni; Joshua D Mezrich Journal: Ann Surg Date: 2017-06 Impact factor: 12.969
Authors: A D B Melo; H Silveira; F B Luciano; C Andrade; L B Costa; M H Rostagno Journal: Asian-Australas J Anim Sci Date: 2016-01 Impact factor: 2.509